Symbols / SGMT
SGMT Chart
About
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 198.38M |
| Enterprise Value | 75.95M | Income | -57.67M | Sales | — |
| Book/sh | 3.67 | Cash/sh | 3.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -3.16 | PEG | — |
| P/S | — | P/B | 1.66 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 12.76 |
| Current Ratio | 13.06 | Debt/Eq | 0.10 | LT Debt/Eq | — |
| EPS (ttm) | -1.78 | EPS next Y | -1.93 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-11 | ROA | -26.52% |
| ROE | -39.78% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 31.00M |
| Shs Float | 28.96M | Short Float | 11.86% | Short Ratio | 4.89 |
| Short Interest | — | 52W High | 11.41 | 52W Low | 1.73 |
| Beta | 3.44 | Avg Volume | 653.22K | Volume | 264.61K |
| Target Price | $25.78 | Recom | Strong_buy | Prev Close | $5.92 |
| Price | $6.10 | Change | 3.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.78
Mean price target
2. Current target
$5.92
Latest analyst target
3. DCF / Fair value
$-15.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.92
Low
$8.00
High
$35.00
Mean
$25.78
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-03 | init | Guggenheim | — → Buy | $27 |
| 2026-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $29 |
| 2026-01-28 | init | Barclays | — → Equal-Weight | $8 |
| 2025-11-14 | main | Citizens | Market Outperform → Market Outperform | $35 |
| 2025-10-22 | init | Clear Street | — → Buy | $29 |
| 2025-10-02 | main | Canaccord Genuity | Buy → Buy | $28 |
| 2025-08-11 | init | Wedbush | — → Outperform | $28 |
| 2025-07-24 | init | Canaccord Genuity | — → Buy | $28 |
| 2025-06-06 | main | Jones Trading | Buy → Buy | $27 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-01-27 | init | Jones Trading | — → Buy | $42 |
| 2024-12-06 | init | Oppenheimer | — → Outperform | $30 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-11-12 | init | UBS | — → Buy | $12 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-10-02 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-08-15 | main | JMP Securities | Market Outperform → Market Outperform | $32 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-07-01 | main | Goldman Sachs | Neutral → Neutral | $6 |
- Biotech Sagimet lines up three March investor conferences - Stock Titan Wed, 25 Feb 2026 12
- $SGMT stock is up 14% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 19
- Sagimet Biosciences to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative Wed, 25 Feb 2026 12
- Price-Driven Insight from (SGMT) for Rule-Based Strategy - Stock Traders Daily Sat, 21 Feb 2026 16
- Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks - Yahoo Finance ue, 16 Sep 2025 07
- Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT) - Seeking Alpha Fri, 19 Dec 2025 08
- Why Sagimet Biosciences (SGMT) Is Up 7.7% After Denifanstat’s Phase 3 Acne Success And What's Next - simplywall.st Wed, 04 Feb 2026 08
- Once-a-day acne pill shows 40-week safety in 240 Chinese patients - Stock Titan hu, 29 Jan 2026 08
- Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts - Seeking Alpha ue, 18 Nov 2025 08
- While institutions own 29% of Sagimet Biosciences Inc. (NASDAQ:SGMT), individual investors are its largest shareholders with 45% ownership - Yahoo Finance ue, 11 Nov 2025 08
- $SGMT stock is up 7% today. Here's what we see in our data. - Quiver Quantitative Fri, 30 Jan 2026 08
- Hear Sagimet Biosciences at Guggenheim and Oppenheimer investor events - Stock Titan hu, 05 Feb 2026 08
- After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - Yahoo Finance Wed, 20 Aug 2025 07
- Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan Wed, 10 Dec 2025 08
- Insider Sale: Executive Chairman of $SGMT Sells 37,688 Shares | SGMT Stock News - Quiver Quantitative Fri, 21 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3640 | 19511 | — | Sale at price 5.36 per share. | MARTINS EDUARDO BRUNO | Officer | — | 2026-02-10 00:00:00 | D |
| 1 | 1312 | 7033 | — | Sale at price 5.36 per share. | CHAUCHE THIERRY | Chief Financial Officer | — | 2026-02-10 00:00:00 | D |
| 2 | 2622 | 14054 | — | Sale at price 5.36 per share. | ROZEK ELIZABETH | Officer | — | 2026-02-10 00:00:00 | D |
| 3 | 12101 | 64865 | — | Sale at price 5.36 per share. | HAPPEL DAVID | Chief Executive Officer | — | 2026-02-10 00:00:00 | D |
| 4 | 37688 | 289979 | — | Sale at price 7.69 per share. | KEMBLE GEORGE | Officer and Director | — | 2025-11-20 00:00:00 | D |
| 5 | 9855 | — | — | Stock Award(Grant) at price 0.00 per share. | ROZEK ELIZABETH | Officer | — | 2025-11-04 00:00:00 | D |
| 6 | 8277 | 75607 | — | Sale at price 9.13 per share. | MARTINS EDUARDO BRUNO | Officer | — | 2025-07-21 00:00:00 | D |
| 7 | 10780 | 98471 | — | Sale at price 9.13 per share. | ROZEK ELIZABETH | General Counsel | — | 2025-07-21 00:00:00 | D |
| 8 | 65478 | 598115 | — | Sale at price 9.13 per share. | HAPPEL DAVID | Chief Executive Officer | — | 2025-07-21 00:00:00 | D |
| 9 | 34000 | — | — | Stock Award(Grant) at price 0.00 per share. | MARTINS EDUARDO BRUNO | Officer | — | 2025-02-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -54.45M | -30.74M | -31.06M | -22.97M |
| TotalUnusualItems | 4.00K | 3.00K | -749.00K | |
| TotalUnusualItemsExcludingGoodwill | 4.00K | 3.00K | -749.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -45.57M | -27.88M | -30.50M | -24.44M |
| EBITDA | -54.45M | -30.74M | -31.05M | -23.72M |
| EBIT | -54.45M | -30.74M | -31.05M | -23.72M |
| NetInterestIncome | 8.89M | 2.86M | 553.00K | 26.00K |
| InterestIncome | 8.89M | 2.86M | 553.00K | 26.00K |
| NormalizedIncome | -45.57M | -27.88M | -30.50M | -23.69M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -45.57M | -27.88M | -30.50M | -24.44M |
| TotalExpenses | 54.45M | 32.74M | 31.05M | 23.72M |
| TotalOperatingIncomeAsReported | -54.45M | -30.74M | -31.05M | -23.72M |
| DilutedAverageShares | 31.35M | 10.46M | 22.17M | 22.17M |
| BasicAverageShares | 31.35M | 10.46M | 22.17M | 22.17M |
| DilutedEPS | -1.45 | -2.66 | -1.38 | -1.10 |
| BasicEPS | -1.45 | -2.66 | -1.38 | -1.10 |
| DilutedNIAvailtoComStockholders | -45.57M | -27.88M | -30.50M | -24.44M |
| NetIncomeCommonStockholders | -45.57M | -27.88M | -30.50M | -24.44M |
| NetIncome | -45.57M | -27.88M | -30.50M | -24.44M |
| NetIncomeIncludingNoncontrollingInterests | -45.57M | -27.88M | -30.50M | -24.44M |
| NetIncomeContinuousOperations | -45.57M | -27.88M | -30.50M | -24.44M |
| PretaxIncome | -45.57M | -27.88M | -30.50M | -24.44M |
| OtherIncomeExpense | 4.00K | 3.00K | -749.00K | |
| OtherNonOperatingIncomeExpenses | 3.00K | -749.00K | ||
| GainOnSaleOfSecurity | 4.00K | 3.00K | -749.00K | |
| NetNonOperatingInterestIncomeExpense | 8.89M | 2.86M | 553.00K | 26.00K |
| InterestIncomeNonOperating | 8.89M | 2.86M | 553.00K | 26.00K |
| OperatingIncome | -54.45M | -30.74M | -31.05M | -23.72M |
| OperatingExpense | 54.45M | 32.74M | 31.05M | 23.72M |
| ResearchAndDevelopment | 38.44M | 19.78M | 24.92M | 19.34M |
| SellingGeneralAndAdministration | 16.01M | 12.96M | 6.14M | 4.38M |
| GeneralAndAdministrativeExpense | 16.01M | 12.96M | 6.14M | 4.38M |
| OtherGandA | 16.01M | 12.96M | 6.14M | 4.38M |
| TotalRevenue | 0.00 | 2.00M | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 2.00M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 32.20M | 22.90M | 22.17M | 22.17M |
| ShareIssued | 32.20M | 22.90M | 22.17M | 22.17M |
| TotalDebt | 78.00K | 65.00K | 211.00K | 348.00K |
| TangibleBookValue | 155.81M | 91.06M | -186.95M | -158.26M |
| InvestedCapital | 155.81M | 91.06M | -186.95M | -158.26M |
| WorkingCapital | 148.32M | 90.99M | 27.51M | 56.22M |
| NetTangibleAssets | 155.81M | 91.06M | -186.95M | -158.26M |
| CapitalLeaseObligations | 78.00K | 65.00K | 211.00K | 348.00K |
| CommonStockEquity | 155.81M | 91.06M | -186.95M | -158.26M |
| TotalCapitalization | 155.81M | 91.06M | -186.95M | -158.26M |
| TotalEquityGrossMinorityInterest | 155.81M | 91.06M | -186.95M | -158.26M |
| StockholdersEquity | 155.81M | 91.06M | -186.95M | -158.26M |
| GainsLossesNotAffectingRetainedEarnings | 230.00K | 30.00K | -84.00K | 0.00 |
| OtherEquityAdjustments | 230.00K | 30.00K | -84.00K | |
| RetainedEarnings | -295.31M | -249.74M | -221.87M | -191.37M |
| AdditionalPaidInCapital | 450.88M | 340.78M | 35.00M | 33.11M |
| CapitalStock | 3.00K | 2.00K | 1.00K | 1.00K |
| CommonStock | 3.00K | 2.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 4.45M | 5.65M | 219.98M | 217.29M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 214.70M | 214.85M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 214.62M | 214.63M | |
| DerivativeProductLiabilities | 0.00 | 4.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 78.00K | 224.00K | |
| LongTermCapitalLeaseObligation | 0.00 | 78.00K | 224.00K | |
| CurrentLiabilities | 4.45M | 5.65M | 5.28M | 2.44M |
| OtherCurrentLiabilities | 5.00K | 233.00K | 57.00K | 185.00K |
| CurrentDebtAndCapitalLeaseObligation | 78.00K | 65.00K | 133.00K | 124.00K |
| CurrentCapitalLeaseObligation | 78.00K | 65.00K | 133.00K | 124.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.10M | 636.00K | 463.00K | |
| PayablesAndAccruedExpenses | 4.37M | 5.36M | 5.09M | 2.13M |
| CurrentAccruedExpenses | 2.95M | 5.17M | 3.96M | 1.37M |
| Payables | 1.43M | 186.00K | 1.12M | 761.00K |
| AccountsPayable | 1.43M | 186.00K | 1.12M | 761.00K |
| TotalAssets | 160.26M | 96.72M | 33.03M | 59.03M |
| TotalNonCurrentAssets | 7.49M | 73.00K | 239.00K | 369.00K |
| NonCurrentPrepaidAssets | 0.00 | 27.00K | 27.00K | |
| InvestmentsAndAdvances | 7.41M | 0.00 | ||
| InvestmentinFinancialAssets | 7.41M | 0.00 | ||
| AvailableForSaleSecurities | 7.41M | |||
| NetPPE | 77.00K | 73.00K | 212.00K | 342.00K |
| GrossPPE | 77.00K | 73.00K | 212.00K | 342.00K |
| OtherProperties | 77.00K | 73.00K | 212.00K | 342.00K |
| CurrentAssets | 152.77M | 96.65M | 32.79M | 58.66M |
| OtherCurrentAssets | 157.00K | 74.00K | 34.00K | 84.00K |
| CurrentDeferredAssets | 306.00K | 323.00K | 0.00 | 1.43M |
| PrepaidAssets | 1.06M | 1.35M | 413.00K | 423.00K |
| CashCashEquivalentsAndShortTermInvestments | 151.25M | 94.90M | 32.34M | 56.73M |
| OtherShortTermInvestments | 75.41M | 19.76M | 32.19M | 0.00 |
| CashAndCashEquivalents | 75.84M | 75.14M | 158.00K | 56.73M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -42.44M | -23.77M | -24.49M | -21.71M |
| IssuanceOfCapitalStock | 105.75M | 89.68M | 0.00 | 10.80M |
| EndCashPosition | 75.84M | 75.14M | 158.00K | 56.73M |
| BeginningCashPosition | 75.14M | 158.00K | 56.73M | 68.70M |
| ChangesInCash | 701.00K | 74.98M | -56.57M | -11.97M |
| FinancingCashFlow | 104.82M | 86.17M | -73.00K | 9.74M |
| CashFlowFromContinuingFinancingActivities | 104.82M | 86.17M | -73.00K | 9.74M |
| NetOtherFinancingCharges | -1.04M | -3.52M | -85.00K | -1.25M |
| ProceedsFromStockOptionExercised | 114.00K | 6.00K | 12.00K | 189.00K |
| NetPreferredStockIssuance | 0.00 | 10.80M | ||
| PreferredStockIssuance | 0.00 | 10.80M | ||
| NetCommonStockIssuance | 105.75M | 89.68M | 0.00 | |
| CommonStockIssuance | 105.75M | 89.68M | 0.00 | |
| InvestingCashFlow | -61.68M | 12.58M | -32.01M | 0.00 |
| CashFlowFromContinuingInvestingActivities | -61.68M | 12.58M | -32.01M | 0.00 |
| NetInvestmentPurchaseAndSale | -61.68M | 12.58M | -32.01M | 0.00 |
| SaleOfInvestment | 46.40M | 32.20M | 9.44M | 0.00 |
| PurchaseOfInvestment | -108.09M | -19.62M | -41.45M | 0.00 |
| OperatingCashFlow | -42.44M | -23.77M | -24.49M | -21.71M |
| CashFlowFromContinuingOperatingActivities | -42.44M | -23.77M | -24.49M | -21.71M |
| ChangeInWorkingCapital | -1.05M | -978.00K | 4.21M | -55.00K |
| ChangeInOtherCurrentLiabilities | -136.00K | -146.00K | -137.00K | -144.00K |
| ChangeInPayablesAndAccruedExpense | -907.00K | 120.00K | 2.92M | 560.00K |
| ChangeInPrepaidAssets | -5.00K | -952.00K | 1.44M | -471.00K |
| OtherNonCashItems | 145.00K | 139.00K | 130.00K | 134.00K |
| StockBasedCompensation | 5.29M | 4.99M | 1.88M | 1.90M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 751.00K | ||
| AmortizationOfSecurities | -1.25M | -37.00K | -212.00K | 0.00 |
| OperatingGainsLosses | -4.00K | -3.00K | -2.00K | |
| GainLossOnInvestmentSecurities | -4.00K | -3.00K | -2.00K | |
| NetIncomeFromContinuingOperations | -45.57M | -27.88M | -30.50M | -24.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SGMT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|